Success Metrics

Active Trials
2(33%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
2
33%
Ph not_applicable
2
33%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Not yet recruiting4
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 31 (16.7%)
N/A2 (33.3%)

Trials by Status

not_yet_recruiting467%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis

NCT07728201
not_yet_recruitingphase_2

Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

NCT07713745
not_yet_recruitingphase_1

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

NCT07708285
recruitingnot_applicable

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

NCT07431060
recruitingnot_applicable

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

NCT07371182
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07728201Phase 2

Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis

Not Yet Recruiting
NCT07713745Phase 2

Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

Not Yet Recruiting
NCT07708285Phase 1

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

Not Yet Recruiting
NCT07431060Not Applicable

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

Recruiting
NCT07371182Not Applicable

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

Recruiting
NCT07004075Phase 3

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

Not Yet Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6